Acquisition by Sean Power of 85000 shares of TG Therapeutics subject to Rule 16b-3

TGTX Stock  USD 31.07  2.50  7.45%   
Slightly above 53% of TG Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding TG Therapeutics suggests that many traders are impartial. TG Therapeutics' investing sentiment can be driven by a variety of factors including economic data, TG Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Tg Therapeutics Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
TG Therapeutics insider trading alert for grant of common stock by Sean Power, Chief Financial Officer, on 14th of March 2023. This event was filed by Tg Therapeutics Inc with SEC on 2023-03-14. Statement of changes in beneficial ownership - SEC Form 4. Sean Power currently serves as cfo, treasurer, corporate secretary of TG Therapeutics

TG Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards TG Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

TG Therapeutics Fundamental Analysis

We analyze TG Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TG Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TG Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Market Capitalization

Market Capitalization Comparative Analysis

TG Therapeutics is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

TG Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TG Therapeutics stock to make a market-neutral strategy. Peer analysis of TG Therapeutics could also be used in its relative valuation, which is a method of valuing TG Therapeutics by comparing valuation metrics with similar companies.

Peers

TG Therapeutics Related Equities

XFORX4 Pharmaceuticals   13.85   
0%
100.0%
HEPAHepion Pharmaceuticals   7.69   
0%
55.0%
PDSBPDS Biotechnology   1.03   
0%
7.0%
VKTXViking Therapeutics   1.12   
8.0%
0%
TERNTerns Pharmaceuticals   2.58   
18.0%
0%
EXELExelixis   2.97   
21.0%
0%
MDGLMadrigal Pharmaceuticals   4.35   
31.0%
0%
BTAIBioXcel Therapeutics   4.88   
35.0%
0%
AKROAkero Therapeutics   6.21   
44.0%
0%

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.